Get the Stockscreener App
54.35
0.31%
-0.17
After Hours:
54.35
Protagonist Therapeutics Inc stock is traded at $54.35, with a volume of 851.96K.
It is down -0.31% in the last 24 hours and up +41.06% over the past month.
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.
See More
Previous Close:
$54.52
Open:
$54.45
24h Volume:
851.96K
Relative Volume:
1.05
Market Cap:
$3.34B
Revenue:
$45.48M
Net Income/Loss:
$169.95M
P/E Ratio:
20.74
EPS:
2.62
Net Cash Flow:
$230.85M
1W Performance:
-5.72%
1M Performance:
+41.06%
6M Performance:
+18.36%
1Y Performance:
+88.58%
1-Day Range:
$52.43
$54.54
1-Week Range:
$51.84
$58.70
52-Week Range:
$24.22
$60.60
Protagonist Therapeutics Inc Stock (PTGX) Company Profile
Name
Protagonist Therapeutics Inc
Sector
Industry
Phone
(510) 474-0170
Address
7707 GATEWAY BLVD., SUITE 140, NEWARK, CA
Compare PTGX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PTGX
Protagonist Therapeutics Inc
|
54.35 | 3.34B | 45.48M | 169.95M | 230.85M | 2.62 |
|
VRTX
Vertex Pharmaceuticals Inc
|
512.52 | 131.61B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
672.36 | 73.51B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
619.97 | 37.67B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
253.44 | 32.81B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
266.26 | 28.62B | 3.81B | -644.79M | -669.77M | -6.24 |
Protagonist Therapeutics Inc Stock (PTGX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-06-24 | Initiated | BMO Capital Markets | Outperform |
| Dec-06-24 | Initiated | Goldman | Neutral |
| Nov-05-24 | Initiated | Wedbush | Outperform |
| Sep-24-24 | Initiated | TD Cowen | Buy |
| Sep-09-24 | Initiated | Truist | Buy |
| Oct-30-23 | Initiated | CapitalOne | Overweight |
| May-25-23 | Resumed | Jefferies | Buy |
| Aug-25-22 | Initiated | JMP Securities | Mkt Outperform |
| Feb-11-22 | Initiated | BTIG Research | Buy |
| Oct-12-21 | Upgrade | JP Morgan | Neutral → Overweight |
| Oct-11-21 | Upgrade | Northland Capital | Market Perform → Outperform |
| Sep-20-21 | Downgrade | JP Morgan | Overweight → Neutral |
| May-24-21 | Initiated | JMP Securities | Mkt Outperform |
| May-24-21 | Initiated | Northland Capital | Outperform |
| Jan-06-21 | Initiated | JP Morgan | Overweight |
| Dec-16-20 | Initiated | Piper Sandler | Overweight |
| Sep-18-20 | Reiterated | H.C. Wainwright | Buy |
| Jul-15-20 | Initiated | Jefferies | Buy |
| May-18-20 | Reiterated | H.C. Wainwright | Buy |
| Jul-08-19 | Initiated | H.C. Wainwright | Buy |
| May-09-19 | Upgrade | Stifel | Hold → Buy |
| Dec-06-18 | Initiated | Nomura | Buy |
| Jan-29-18 | Initiated | Stifel | Buy |
| Jul-21-17 | Initiated | BTIG Research | Buy |
View All
Protagonist Therapeutics Inc Stock (PTGX) Latest News
Protagonist Therapeutics director Waddill sells $217,000 in stock - Investing.com
Protagonist Therapeutics director Waddill sells $217,000 in stock By Investing.com - Investing.com UK
Analysts Mentions Growth Catalysts for Protagonist Therapeutics (PTGX) — Best Biotech Stock for 2025? - MSN
Protagonist Therapeutics Named to Fast Company's Annual List of the World's Most Innovative Companies of 2025 - Bluefield Daily Telegraph
Fast Company Ranks Protagonist Among Elite Biotech Innovators: 2 FDA Filings Coming - StockTitan
Is Protagonist Therapeutics, Inc. (PTGX) the Best Healthcare Stock For Long-Term Investment? - Insider Monkey
Protagonist Therapeutics CFO Ali Asif sells $1.46 million in stock By Investing.com - Investing.com South Africa
Protagonist Therapeutics’ chief medical officer sells $1.7 million in stock By Investing.com - Investing.com Australia
Protagonist Therapeutics’ chief medical officer sells $1.7 million in stock - Investing.com India
Protagonist Therapeutics CFO Ali Asif sells $1.46 million in stock - Investing.com
Protagonist Therapeutics (NASDAQ:PTGX) Price Target Raised to $76.00 - Defense World
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Shares Purchased by Victory Capital Management Inc. - Defense World
Protagonist Therapeutics Unveils 'Paradigm-Shifting' Drug And Breaks Out - MSN
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Shares Acquired by Bank of New York Mellon Corp - Defense World
Protagonist Therapeutics’ SWOT analysis: promising pipeline drives stock outlook By Investing.com - Investing.com South Africa
Protagonist Therapeutics’ SWOT analysis: promising pipeline drives stock outlook - Investing.com
Protagonist Therapeutics (PTGX) Upgraded to Buy: Here's Why - Yahoo Finance
Learn to Evaluate (PTGX) using the Charts - Stock Traders Daily
Protagonist Therapeutics (NASDAQ:PTGX) Price Target Raised to $72.00 at BMO Capital Markets - Defense World
Protagonist Therapeutics (NASDAQ:PTGX) Hits New 1-Year High on Analyst Upgrade - Defense World
Protagonist Therapeutics: Much More Than Rusfertide In Place To Carry It (NASDAQ:PTGX) - Seeking Alpha
Wedbush Adjusts Protagonist Therapeutics Price Target to $70 From $58, Maintains Outperform Rating - Marketscreener.com
Protagonist Therapeutics Soars as Icotrokinra Drives Breakthroug - GuruFocus.com
Protagonist Therapeutics price target raised to $76 from $60 at Truist - TipRanks
Protagonist Therapeutics Soars as Icotrokinra Drives Breakthrough Success - Yahoo Finance UK
Gilead Sciences To Rally Around 11%? Here Are 10 Top Analyst Forecasts For Tuesday - Benzinga
Protagonist Therapeutics price target raised to $72 from $62 at BMO Capital - TipRanks
Why Protagonist Therapeutics, Inc. (PTGX) Went Up on Monday - MSN
Protagonist Therapeutics, Inc.'s (NASDAQ:PTGX) Shares Climb 44% But Its Business Is Yet to Catch Up - Simply Wall St
Protagonist Therapeutics price target raised to $80 from $54 at H.C. Wainwright - TipRanks
Protagonist Therapeutics Gets IBD Stock Rating Upgrade - Investor's Business Daily
10 Firms Buck Market Bloodbath on Monday - Insider Monkey
Protagonist Therapeutics’ (PTGX) Buy Rating Reaffirmed at HC Wainwright - Defense World
PTGX stock soars to 52-week high, reaching $50.18 By Investing.com - Investing.com Australia
BTIG maintains Buy on Protagonist Therapeutics, target at $73 By Investing.com - Investing.com Canada
Truist raises Protagonist Therapeutics target to $76 - Investing.com
Truist raises Protagonist Therapeutics target to $76 By Investing.com - Investing.com UK
Why Is Protagonist Therapeutics Stock Trading Higher On Monday? - Benzinga
Truist Securities Adjusts Price Target on Protagonist Therapeutics to $76 From $60, Keeps Buy Rating - Marketscreener.com
Protagonist Therapeutics rises as bowel disease drug succeeds mid-stage study - TradingView
Protagonist reports top line results from Phase 2b study of icotrokinra - TipRanks
PTGX stock soars to 52-week high, reaching $50.18 - Investing.com India
Why Protagonist Therapeutics Shares Are Under Pressure - TipRanks
Protagonist Reports Positive Top Line Results From Phase 2b Study of Icotrokinra Showing Potential to Transform the Treatment Paradigm for Patients With Ulcerative Colitis - ACCESS Newswire
BTIG maintains Buy on Protagonist Therapeutics, target at $73 - Investing.com India
JMP reiterates $61 target for Protagonist Therapeutics stock - Investing.com
JMP reiterates $61 target for Protagonist Therapeutics stock By Investing.com - Investing.com Canada
Promising Potential of Protagonist Therapeutics’ Icotrokinra in Psoriasis Treatment: A New Benchmark for Oral Therapies - TipRanks
Protagonist Therapeutics: Buy Rating Backed by Promising Phase 3 Results and Market Potential of Icotrokinra - TipRanks
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Receives $55.89 Average Price Target from Analysts - Defense World
Protagonist Therapeutics Inc (PTGX) Announces Promising Phase 3 Results for Icotrokinra in Psoriasis Treatment - GuruFocus.com
Protagonist Therapeutics Inc Stock (PTGX) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.53%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):